Published by Josh White on 2nd June 2025
(Sharecast News) - Hutchmed China reported positive interim results from its phase three 'SACHI' trial on Monday, showing that the combination of savolitinib and osimertinib significantly improved progression-free survival (PFS) in patients with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) and MET amplification, following progression on first-line EGFR inhibitor therapy.